(Q34026011)

30 July 2017

1 reference

title

Risk of osteoporosis and fracture incidence in patients on antipsychotic medication (English)

1 reference

30 July 2017

0 references

1 reference

Evangelia Maria Tsapakis

1 reference

ORCID Public Data File 2021

author name string

Simon Matthew Graham

1

1 reference

30 July 2017

Daniel Howgate

2

1 reference

30 July 2017

William Anderson

3

1 reference

30 July 2017

Claire Howes

4

1 reference

30 July 2017

Manolis Heliotis

5

1 reference

30 July 2017

Athanassios Mantalaris

6

1 reference

30 July 2017

Eleftherios Tsiridis

7

1 reference

30 July 2017

Evangelia Tsapakis

8

1 reference

30 July 2017

language of work or name

English

0 references

publication date

9 March 2011

1 reference

Expert Opinion on Drug Safety

30 July 2017

published in

1 reference

30 July 2017

volume

10

1 reference

30 July 2017

issue

4

1 reference

30 July 2017

page(s)

575-602

1 reference

Risk of hip/femur fractures in patients using antipsychotics

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Long-term effects of the substituted benzamide derivative amisulpride on baseline and stimulated prolactin levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Risk of hip fracture in patients with a history of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Ultrasound bone mass in schizophrenic patients on antipsychotic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Prolactin decreases expression of Runx2, osteoprotegerin, and RANKL in primary osteoblasts derived from tibiae of adult female rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Mechanisms of action of atypical antipsychotic drugs: a critical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Prolactin levels and adverse events in patients treated with risperidone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Dopamine receptors and brain function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Prolactin-Lowering and -Releasing Drugs Mechanisms of Action and Therapeutic Applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Endocrinological responses to 5-HT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Prolactin and schizophrenia: clinical consequences of hyperprolactinaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Prolactinemia is uncoupled from central D2/D3 dopamine receptor occupancy in amisulpride treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Neuroendocrine responsivities of the pituitary dopamine system in male schizophrenic patients during treatment with clozapine, olanzapine, risperidone, sulpiride, or haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Prolactin and antipsychotic medications: mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences. Selective literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

The discriminant dopamine antagonist property of benzamides is observed at various times after their systemic or intracerebroventricular administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Circadian rhythm of tryptophan, serotonin, melatonin, and pituitary hormones in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Relationship between Taq1 A dopamine D2 receptor (DRD2) polymorphism and prolactin response to bromperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Osteoporosis and its management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Osteoporosis: a still increasing prevalence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Epidemiology and outcomes of osteoporotic fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Involutional osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Evidence for direct effects of prolactin on human osteoblasts: Inhibition of cell growth and mineralization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Managing osteoporosis in patients with fragility fractures: did the British Orthopaedic Association guidelines have any impact?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

The Effect of Neuroleptics on Serum Prolactin in Schizophrenic Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

A study of serum prolactin levels in schizophrenia: comparison of males and females

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Osteoporosis in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Elevation of prolactin levels by atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Risperidone-associated hyperprolactinemia: evaluation in twenty psychiatric outpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Impact of risperidone medication on quality of life and gonadal axis hormones in schizophrenia male patients with acute exacerbation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Risperidone-induced increase in serum prolactin is correlated with positive symptom improvement in chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Prolactin level during 5 years of risperidone treatment in patients with psychotic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Risperidone in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Prolactin levels in male schizophrenic patients treated with risperidone and haloperidol: a double-blind and randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Effect of risperidone and olanzapine on reproductive hormones, psychopathology and sexual functioning in male patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Radioreceptor binding profile of the atypical antipsychotic olanzapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

The effect of clozapine on prolactin secretion at the level of the lactotroph.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Atypical antipsychotics: are some more atypical than others?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Possible individual and gender differences in the small increases in plasma prolactin levels seen during clozapine treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Attenuation of antipsychotic-induced hyperprolactinemia with clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Seroquel: biochemical profile of a potential atypical antipsychotic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Efficacy and tolerability of quetiapine in poorly responsive, chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

The relationship between prolactin response and clinical efficacy of risperidone in acute psychotic inpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Prolactin directly enhances bone turnover by raising osteoblast-expressed receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Bone calcium turnover, formation, and resorption in bromocriptine- and prolactin-treated lactating rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Enhanced trabecular-bone calcium deposition in female rats with a high physiological dose of prolactin diminishes after ovariectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Bone mineral density and prolactin associations in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Decreased bone mineral density in medicated psychiatric patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Antipsychotic use and the risk of hip/femur fracture: a population-based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Psychotropic drug use and the risk of hip fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Epidemiology of hip fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

Bone mass in schizophrenia and normal populations across different decades of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560112

10.1517/14740338.2011.560112

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference